Citation:De Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al 2011

Citation

de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011 Mar 10;29(8):1067-74 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21282537.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
De Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al 2011	What is the optimal systemic therapy for stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
De Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al 2011 2	What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
De Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al 2011 3	What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
2. What is the optimal systemic therapy for stage IV inoperable NSCLC?